Skip to main content
SpringerLink
Log in

A Critical Approach to Clinical Biochemistry of Chromogranin A

  • Chapter
Advances in Cancer Biomarkers

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 867))

Abstract

Chromogranin A (CGA) is a member of the granin family of proteins which are widespread in endocrine, neuroendocrine, peripheral, and central nervous tissues, where they are typically found in secretory granules. It is well accepted that CGA cooperates to regulate synthesis and secretion of these various granule signaling molecules.

Because of its ubiquitous distribution within neuroendocrine tissues, CGA can be a useful diagnostic marker for neuroendocrine neoplasms, including carcinoids, pheochromocytomas, neuroblastomas, medullary thyroid carcinomas (MTC), some pituitary tumors, functioning and nonfunctioning islet cell tumors and other amine precursor uptake and decarboxylation (APUD) tumors. It is also useful as a prognostic marker for detection of recurrence and monitoring of response to different treatments. As other tumor markers, it is imperative to know its physiology and pathophysiology, its sensitivity and specificity in different neuroendocrine tumors (NETs), and carefully integrate these data with the clinical data of the single patient, to maximize its diagnostic/prognostic index.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Simon JP, Aunis D (1989) Biochemistry of the chromogranin A protein family. Biochem J 262:1–13

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Sokoll LJ, Rai AJ, Chan DW (2012) Tumor markers. In: Burtis CA, Ashwood ER, Bruns DE (eds) Tietz textbook of clinical chemistry and molecular diagnostics. Elsevier-Saunders, St.Louis, p 650

    Google Scholar 

  3. D’Amico MA, Ghinassi B, Izzicupo P, Manzoli L, Di Baldassarre A (2014) Biological function and clinical relevance of chromogranin A and derived peptides. Endocr Connect 3:R45–R54

    Article  PubMed  Google Scholar 

  4. Bartolomucci A, Possenti R, Mahata SK et al (2011) The extended granin family: structure, function, and biomedical implications. Endocr Rev 32:755–797

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Borges R, Dominguez N, Smith CB, Bandyopadhyay GK, O’Connor DT, Mahata SK, Bartolomucci A (2013) Granins and catecholamines: functional interaction in chromaffin cells and adipose tissue. Adv Pharmacol 68:93–113

    Article  CAS  PubMed  Google Scholar 

  6. Gerdes HH, Glombik MM (2000) Signal-mediated sorting of chromogranins to secretory granules. Adv Exp Med Biol 482:41–54

    Article  CAS  PubMed  Google Scholar 

  7. Aunis D, Metz-Boutigue MH (2000) Chromogranins: current concepts. Structural and functional aspects. Adv Exp Med Biol 482:21–38

    Article  CAS  PubMed  Google Scholar 

  8. Wu Z, Sun L, Hashioka S, Yu S, Schwab C, Okada R, Hayashi Y, McGeer PL, Nakanishi H (2013) Differential pathways for interleukin-1β production activated by chromogranin A and amyloid β in microglia. Neurobiol Aging 34:2715–2725

    Article  CAS  PubMed  Google Scholar 

  9. Jakobsson J, Stridsberg M, Zetterberg H, Blennow K, Ekman CJ, Johansson AG, Sellgren C, Landén M (2013) Decreased cerebrospinal fluid secretogranin II concentrations in severe forms of bipolar disorder. J Psychiatry Neurosci 38:E21–E26

    Article  PubMed Central  PubMed  Google Scholar 

  10. Plá V, Paco S, Ghezali G, Ciria V, Pozas E, Ferrer I, Aguado F (2013) Secretory sorting receptors carboxypeptidase E and secretogranin III in amyloid β-associated neural degeneration in Alzheimer’s disease. Brain Pathol 23:274–284

    Article  PubMed  Google Scholar 

  11. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, van Beveren NJ, Spain M, Barnes A, Steiner J, Rahmoune H, Bahn S (2011) Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36:1092–1096

    Article  CAS  PubMed  Google Scholar 

  12. Goetze JP, Alehagen U, Flyvbjerg A, Rehfeld JF (2013) Making sense of chromogranin A in heart disease. Lancet Diab Endocrinol 1:7–8

    Article  Google Scholar 

  13. Goetze JP, Alehagen U, Flyvbjerg A, Rehfeld JF (2014) Chromogranin A as a biomarker in cardiovascular disease. Biomark Med 8:133–140

    Article  CAS  PubMed  Google Scholar 

  14. Zhang K, Rao F, Wang L, Rana BK, Ghosh S, Mahata M, Salem RM, Rodriguez-Flores JL, Fung MM, Waalen J, Tayo B, Taupenot L, Mahata SK, O’Connor DT (2010) Common functional genetic variants in catecholamine storage vesicle protein promoter motifs interact to trigger systemic hypertension. J Am Coll Cardiol 55:1463–1475

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Yu L, Jiang L, Zhou XJ, Zhu L, Zhang H (2010) Common genetic variants in the chromogranin a promoter are associated with renal injury in IgA nephropathy patients with malignant hypertension. Ren Fail 32:41–46

    Article  PubMed  Google Scholar 

  16. Wu JT, Erickson AJ, Tsao KC, Wu TL, Sun CF (2000) Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Ann Clin Lab Sci 30:175–178

    PubMed  Google Scholar 

  17. Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F (2013) Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 64:722–730

    Article  PubMed  Google Scholar 

  18. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R, Di Silverio F (2003) Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 55:168–179

    Article  PubMed  Google Scholar 

  19. Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, Reid R, Rowsell C, Shah A, Singh S, Van Uum S, Wong R (2010) Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 17:49–64

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Angelini F, Baldelli R, Berretti D, Bianchetti S, Bizzarri G, Caputo M, Castello R, Cremonini N, Crescenzi A, Davì MV, D’Elia AV, Faggiano A, Pizzolitto S, Versari A, Zini M, Rindi G, Oberg K (2014) Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest 37:875–909

    Article  PubMed Central  PubMed  Google Scholar 

  21. Boudreaux JP, Klimstra DS, Hassan MM et al (2010) The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors-well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 39:753–766

    Article  PubMed  Google Scholar 

  22. Anthony LB, Stosberg JR, Klimstra DS et al (2010) The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors – well-differentiated NETs of the distal colon and rectum. Pancreas 39:767–774

    Article  PubMed  Google Scholar 

  23. Algeciras-Schimnich A, Preissner CM, Young WF et al (2008) Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytomas. J Clin Endocrinol Metab 93:91–95

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Kullke MH, Benson AB, Bergsland E et al (2012) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines): NCCN Guidelines version 1.2012 – neuroendocrine tumors, pp 1–94, E-Pub Date 20 Mar 2012. URL: http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf

  25. van Adrichem RC, Hofland LJ, Feelders RA, De Martino MC, van Koetsveld PM, van Eijck CH, de Krijger RR, Sprij-Mooij DM, Janssen JA, de Herder WW (2013) Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors. Endocr Connect 2:172–177

    Article  PubMed Central  PubMed  Google Scholar 

  26. Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM (2013) Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One 8, e76462

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M (2013) Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 31:1265–1274

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Kratochwil C, López-Benítez R, Mier W, Haufe S, Isermann B, Kauczor HU, Choyke PL, Haberkorn U, Giesel FL (2011) Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer 18:595–602

    Article  CAS  PubMed  Google Scholar 

  29. Lubner SJ, Kunnimalaiyaan M, Holen KD, Ning L, Ndiaye M, Loconte NK, Mulkerin DL, Schelman WR, Chen H (2011) A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. Oncologist 16:452–457

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Wang YH, Yang QC, Lin Y, Xue L, Chen MH, Chen J (2014) Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine 93, e247

    Article  PubMed Central  PubMed  Google Scholar 

  31. Jilesen AP, Busch OR, van Gulik TM, Gouma DJ, Nieveen van Dijkum EJ (2015) Standard pre- and postoperative determination of chromogranin A in resectable non-functioning pancreatic neuroendocrine tumors – diagnostic accuracy: NF-pNET and low tumor burden. Dig Surg 31:407–414

    Article  Google Scholar 

  32. de Laat JM, Pieterman CR, Weijmans M, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD (2013) Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. J Clin Endocrinol Metab 98:4143–4151

    Article  PubMed  Google Scholar 

  33. Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, Wang YH, Chen J, Lu CM (2014) Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord 14:64

    Article  PubMed Central  PubMed  Google Scholar 

  34. Guillemot J, Guérin M, Thouënnon E, Montéro-Hadjadje M, Leprince J, Lefebvre H, Klein M, Muresan M, Anouar Y, Yon L (2014) Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma. PLoS One 9, e88698

    Article  PubMed Central  PubMed  Google Scholar 

  35. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H (2002) Chromogranin aconcentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 167:512–515

    Article  CAS  PubMed  Google Scholar 

  36. Tricoli JV, Schoenfeldt M, Conley BA (2004) Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 10:3943–3953

    Article  PubMed  Google Scholar 

  37. Ferrero-Poüs M, Hersant AM, Pecking A, Brésard-Leroy M, Pichon MF (2001) Serum chromogranin-A in advanced prostate cancer. BJU Int 88:790–796

    Article  PubMed  Google Scholar 

  38. Hirano D, Hasegawa R, Satoh K, Mochida J, Yamanaka Y, Hirakata H, Yamaguchi K, Sugimoto S, Kawata N, Takahashi S (2014) Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy. Scand J Urol 48:436–444

    Article  CAS  PubMed  Google Scholar 

  39. Tarle M, Ahel MZ, Kovacić K (2002) Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res 22:2525–2529

    PubMed  Google Scholar 

  40. Moline J, Eng C (2011) Multiple endocrine neoplasia type 2: an overview. Genet Med 13:755–764

    Article  CAS  PubMed  Google Scholar 

  41. Taïeb D, Kebebew E, Castinetti F, Chen CC, Henry JF, Pacak K (2014) Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. Clin Endocrinol (Oxf) 81:317–328

    Article  Google Scholar 

  42. Bech PR, Ramachandran R, Dhillo WS et al (2012) Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript. Clin Chem 58:941–943

    Article  CAS  PubMed  Google Scholar 

  43. Canale MP, Bravo EL (1994) Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 78:1139–1144

    CAS  PubMed  Google Scholar 

  44. Korse CM, Muller M, Taal BG (2011) Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumors. Br J Cancer 32:1173–1175

    Article  Google Scholar 

  45. Mosli HH, Dennis A, Kosha W, Asher LJ, Van Uum SH (2012) Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. J Clin Endocrinol Metab 97:E1731–E1735

    Google Scholar 

  46. Glinicki P, Kapuścińska R, Jeske W (2013) Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays: the importance of protein matrix effects. Clin Endocrinol (Oxf) 79:295–296

    Article  Google Scholar 

  47. Gruson D, Lepoutre T, Smits F (2015) Chromogranin-A levels measured with automated immunoassay. Int J Biol Markers 30:e132–e135

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Biochemistry and Clinical Biochemistry, Faculty of Medicine, UCSC – Catholic University of Rome, Gemelli Hospital 8, Largo Gemelli, 00168, Rome, Italy

    Patrizia Bottoni, Teresa De Michele & Roberto Scatena

Authors
  1. Patrizia Bottoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teresa De Michele
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto Scatena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Scatena .

Editor information

Editors and Affiliations

  1. Institute of Biochemistry and Clinical B, Catholic University School of Medicine, Rome, Italy

    Roberto Scatena

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Bottoni, P., De Michele, T., Scatena, R. (2015). A Critical Approach to Clinical Biochemistry of Chromogranin A. In: Scatena, R. (eds) Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology, vol 867. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7215-0_19

Download citation

Publish with us

Policies and ethics

Search

Navigation